دورية أكاديمية
أعرض في EDS

The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer.

التفاصيل البيبلوغرافية
العنوان: The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer.
المؤلفون: Grisetti L; Fondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.; Department of Life Sciences, Università degli Studi di Trieste, Trieste, Italy., Garcia CJC; Fondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.; Department of Life Sciences, Università degli Studi di Trieste, Trieste, Italy., Saponaro AA; Fondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy., Tiribelli C; Fondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy., Pascut D; Fondazione Italiana Fegato - ONLUS, Liver Cancer Unit, Trieste, Italy.
المصدر: Cell proliferation [Cell Prolif] 2024 Aug; Vol. 57 (8), pp. e13641. Date of Electronic Publication: 2024 Apr 08.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Published for the Cell Kinetics Society, the European Study Group for Cell Proliferation, and the International Cell Cycle Society by Blackwell Scientific Publications Country of Publication: England NLM ID: 9105195 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2184 (Electronic) Linking ISSN: 09607722 NLM ISO Abbreviation: Cell Prolif Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Oxford, England] : Published for the Cell Kinetics Society, the European Study Group for Cell Proliferation, and the International Cell Cycle Society by Blackwell Scientific Publications, 1991-
مواضيع طبية MeSH: Aurora Kinase A*/metabolism , Aurora Kinase A*/antagonists & inhibitors , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Liver Neoplasms*/drug therapy, Humans ; Epithelial-Mesenchymal Transition ; Tumor Microenvironment ; Animals ; Prognosis ; Cell Movement ; Biomarkers, Tumor/metabolism
مستخلص: Aurora Kinase A (AURKA) plays a central role as a serine/threonine kinase in regulating cell cycle progression and mitotic functions. Over the years, extensive research has revealed the multifaceted roles of AURKA in cancer development and progression. AURKA's dysregulation is frequently observed in various human cancers, including hepatocellular carcinoma (HCC). Its overexpression in HCC has been associated with aggressive phenotypes and poor clinical outcomes. This review comprehensively explores the molecular mechanisms underlying AURKA expression in HCC and its functional implications in cell migration, invasion, epithelial-to-mesenchymal transition, metastasis, stemness, and drug resistance. This work focuses on the clinical significance of AURKA as a diagnostic and prognostic biomarker for HCC. High levels of AURKA expression have been correlated with shorter overall and disease-free survival in various cohorts, highlighting its potential utility as a sensitive prognostic indicator. Recent insights into AURKA's role in modulating the tumour microenvironment, particularly immune cell recruitment, may provide valuable information for personalized treatment strategies. AURKA's critical involvement in modulating cellular pathways and its overexpression in cancer makes it an attractive target for anticancer therapies. This review discusses the evidence about novel and selective AURKA inhibitors for more effective treatments for HCC.
(© 2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.)
References: Clin Cancer Res. 2019 Jun 1;25(11):3229-3238. (PMID: 30777875)
Oncologist. 2022 Aug 5;27(8):646-654. (PMID: 35666660)
BMC Cancer. 2019 Nov 8;19(1):1075. (PMID: 31703572)
J Cell Sci Suppl. 1989;12:277-91. (PMID: 2534556)
Curr Biol. 2002 Dec 10;12(23):2055-9. (PMID: 12477396)
Cancers (Basel). 2023 Nov 16;15(22):. (PMID: 38001709)
Immunol Invest. 2022 Jul;51(5):1211-1221. (PMID: 34018460)
Curr Biol. 2008 Nov 11;18(21):1649-58. (PMID: 18976910)
J Interv Med. 2021 May 15;4(3):105-113. (PMID: 34805958)
Int J Gen Med. 2022 Apr 11;15:3933-3941. (PMID: 35431572)
Biochem Biophys Res Commun. 2017 Apr 29;486(2):514-520. (PMID: 28322787)
Sci Rep. 2017 Jan 19;7:40714. (PMID: 28102366)
Cell Mol Life Sci. 2013 Feb;70(4):661-87. (PMID: 22864622)
Clin Cancer Res. 2011 Dec 15;17(24):7614-24. (PMID: 22016509)
Mol Cancer. 2011 Oct 19;10:131. (PMID: 22011530)
Front Oncol. 2022 Dec 22;12:1010726. (PMID: 36620586)
J Biol Chem. 2012 Mar 2;287(10):7701-16. (PMID: 22262852)
Oncogenesis. 2021 May 15;10(5):41. (PMID: 33993200)
Cancer Gene Ther. 2023 Jul;30(7):1007-1017. (PMID: 36973424)
Curr Biol. 2003 Apr 15;13(8):691-7. (PMID: 12699628)
Open Biol. 2016 Jul;6(7):. (PMID: 27411893)
Sci Rep. 2016 Jun 24;6:28528. (PMID: 27339427)
Open Biol. 2022 Sep;12(9):220134. (PMID: 36067794)
World J Gastroenterol. 2021 Nov 21;27(43):7462-7479. (PMID: 34887643)
J Biol Chem. 2002 Mar 22;277(12):10719-26. (PMID: 11790771)
Cell Div. 2018 Sep 19;13:7. (PMID: 30250494)
Cancer Commun (Lond). 2021 Sep;41(9):851-866. (PMID: 34251762)
J Biomol Struct Dyn. 2023;41(21):11845-11861. (PMID: 36634158)
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18. (PMID: 21293511)
Nat Commun. 2021 Sep 1;12(1):5203. (PMID: 34471141)
Nat Med. 2016 Jul;22(7):744-53. (PMID: 27213815)
Oncotarget. 2017 Apr 25;8(17):27953-27965. (PMID: 28427193)
Mol Cell. 2003 Oct;12(4):851-62. (PMID: 14580337)
EMBO Rep. 2006 Apr;7(4):418-24. (PMID: 16462731)
Oncotarget. 2017 May 9;8(19):32117-32133. (PMID: 28389630)
Exp Ther Med. 2020 Jul;20(1):427-435. (PMID: 32537007)
J Cell Biol. 2012 Apr 2;197(1):19-26. (PMID: 22451695)
Comput Intell Neurosci. 2022 May 18;2022:7102500. (PMID: 35720901)
Sci Signal. 2018 Aug 14;11(543):. (PMID: 30108183)
J Hematol Oncol. 2017 Jun 8;10(1):115. (PMID: 28595628)
Cancers (Basel). 2019 Jul 02;11(7):. (PMID: 31269749)
Front Oncol. 2016 Jan 18;5:307. (PMID: 26835416)
Oncogene. 2000 Oct 5;19(42):4906-16. (PMID: 11039908)
Front Genet. 2021 Nov 30;12:730732. (PMID: 34917126)
Liver Int. 2022 Feb;42(2):468-478. (PMID: 34719108)
Exp Mol Med. 2021 May;53(5):835-847. (PMID: 34050264)
Nucleic Acids Res. 1995 Oct 11;23(19):3822-30. (PMID: 7479023)
Front Oncol. 2021 Jul 16;11:642563. (PMID: 34336648)
Int J Med Sci. 2018 Jan 1;15(2):170-175. (PMID: 29333101)
Curr Cancer Drug Targets. 2017;17(4):386-401. (PMID: 27396604)
J Cell Sci. 2014 Oct 1;127(Pt 19):4111-22. (PMID: 25128564)
Cell. 1995 Apr 7;81(1):95-105. (PMID: 7720077)
Cell Prolif. 2024 Aug;57(8):e13641. (PMID: 38590119)
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021 Mar;37(3):233-239. (PMID: 33766231)
Cancer. 2013 Feb 15;119(4):904-14. (PMID: 22972611)
Antiviral Res. 2019 Oct;170:104572. (PMID: 31376425)
Cancer Manag Res. 2023 Sep 27;15:1053-1062. (PMID: 37790897)
Genome Biol. 2014;15(6):122. (PMID: 25180339)
BMB Rep. 2022 Feb;55(2):87-91. (PMID: 34903321)
Oncotarget. 2017 Jun 27;8(33):54904-54912. (PMID: 28903390)
Ann Transl Med. 2020 Apr;8(7):478. (PMID: 32395522)
J Cell Biol. 2010 Dec 27;191(7):1315-32. (PMID: 21187329)
Am J Med Sci. 2020 Apr;359(4):226-234. (PMID: 32200915)
Theranostics. 2018 Feb 12;8(6):1740-1751. (PMID: 29556353)
Oncotarget. 2016 Aug 2;7(31):50290-50301. (PMID: 27385211)
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819851833. (PMID: 31570091)
Int J Endocrinol. 2014;2014:816430. (PMID: 25097550)
Cancer Cell Int. 2020 Jun 17;20:251. (PMID: 32565735)
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. (PMID: 31439937)
Oncogene. 2017 Jun 15;36(24):3428-3440. (PMID: 28114286)
J Hepatol. 2022 Dec;77(6):1598-1606. (PMID: 36208844)
Cell. 2003 Sep 5;114(5):585-98. (PMID: 13678582)
Aging (Albany NY). 2021 May 4;13(9):12865-12895. (PMID: 33946043)
Mol Cancer Ther. 2009 Jul;8(7):2046-56. (PMID: 19584233)
Elife. 2023 Jan 24;12:. (PMID: 36692000)
Cell Death Dis. 2022 Nov 24;13(11):994. (PMID: 36433941)
J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630)
Mol Cancer Ther. 2019 Dec;18(12):2207-2219. (PMID: 31530649)
FEBS Lett. 2002 May 22;519(1-3):59-65. (PMID: 12023018)
Cancer Biomark. 2020;28(3):341-350. (PMID: 32390596)
Med Oncol. 2022 Jan 4;39(2):21. (PMID: 34982264)
Int J Cancer. 2009 Jan 1;124(1):16-26. (PMID: 18814281)
Int J Mol Sci. 2020 Nov 05;21(21):. (PMID: 33167327)
Oncotarget. 2016 Dec 27;7(52):86239-86256. (PMID: 27863392)
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12983-8. (PMID: 9789027)
Mol Carcinog. 2015 Nov;54(11):1467-79. (PMID: 25284017)
Nucleic Acids Res. 2014;42(16):10331-50. (PMID: 25106871)
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15440-5. (PMID: 12422018)
J Biol Chem. 1997 Apr 4;272(14):9166-74. (PMID: 9083047)
Mol Cancer. 2021 Jan 15;20(1):15. (PMID: 33451333)
Cancer Res. 2011 May 1;71(9):3225-35. (PMID: 21521802)
Medicina (Kaunas). 2019 Aug 23;55(9):. (PMID: 31450841)
JAMA Oncol. 2019 Jan 1;5(1):e183773. (PMID: 30347019)
Nat Commun. 2016 Jan 19;7:10180. (PMID: 26782714)
Cancer Res. 2007 Feb 15;67(4):1689-95. (PMID: 17308110)
Cancer Cell. 2014 Sep 8;26(3):414-427. (PMID: 25175806)
Curr Opin Cell Biol. 2009 Dec;21(6):796-805. (PMID: 19836940)
J Cell Biol. 2003 Sep 1;162(5):757-63. (PMID: 12939255)
Oncogene. 2000 Jun 1;19(24):2812-9. (PMID: 10851084)
Mol Cell. 2010 Aug 13;39(3):477-84. (PMID: 20655260)
Int J Gen Med. 2021 Dec 22;14:10185-10194. (PMID: 34992437)
Front Genet. 2021 Jan 11;11:575762. (PMID: 33505422)
Clin Cancer Res. 2004 Mar 15;10(6):2065-71. (PMID: 15041727)
EMBO J. 1995 Sep 15;14(18):4514-22. (PMID: 7556094)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Nat Cell Biol. 2005 Oct;7(10):937-46. (PMID: 16184168)
J Hepatol. 1999 Jul;31(1):133-41. (PMID: 10424293)
BMJ. 2020 Oct 26;371:m3544. (PMID: 33106289)
Nat Cell Biol. 2002 Nov;4(11):871-9. (PMID: 12389033)
J Int Med Res. 2020 Jul;48(7):300060520910019. (PMID: 32722976)
Int J Genomics. 2020 Jul 28;2020:2061024. (PMID: 32775402)
Genes Cells. 2002 Nov;7(11):1173-82. (PMID: 12390251)
Br J Cancer. 2014 Apr 15;110(8):2090-8. (PMID: 24691419)
J Clin Oncol. 2019 Mar 10;37(8):613-623. (PMID: 30707661)
Med Res Rev. 2016 Nov;36(6):1036-1079. (PMID: 27406026)
J Cell Biol. 2015 Jul 6;210(1):45-62. (PMID: 26124292)
Mol Cancer Ther. 2020 May;19(5):1197-1209. (PMID: 32220970)
Cell Cycle. 2013 Sep 1;12(17):2849-66. (PMID: 23966163)
J Cell Biol. 2002 Aug 19;158(4):617-23. (PMID: 12177045)
RNA Biol. 2021 Jan;18(1):144-156. (PMID: 32757706)
J Med Chem. 2008 Aug 14;51(15):4465-75. (PMID: 18630890)
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5811-6. (PMID: 16581905)
J Clin Lab Anal. 2022 Dec;36(12):e24758. (PMID: 36377304)
PeerJ. 2020 Apr 08;8:e8930. (PMID: 32296612)
ACS Med Chem Lett. 2010 Jun 07;1(5):214-8. (PMID: 24900197)
Ann Oncol. 2015 May;26(5):935-942. (PMID: 25632068)
Dev Cell. 2006 Aug;11(2):147-57. (PMID: 16890155)
Oncotarget. 2016 Nov 22;7(47):78009-78028. (PMID: 27793005)
J Environ Pathol Toxicol Oncol. 2022;41(1):27-43. (PMID: 35378002)
Nat Chem Biol. 2018 Aug;14(8):768-777. (PMID: 29942081)
Oncotarget. 2014 Dec 30;5(24):12916-35. (PMID: 25428915)
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224)
Arch Med Sci. 2019 Dec 31;16(2):395-406. (PMID: 32190151)
Int J Oncol. 2020 Sep;57(3):845-857. (PMID: 32705157)
Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. (PMID: 30032643)
Cell Oncol (Dordr). 2021 Oct;44(5):1035-1049. (PMID: 34176092)
Oncogene. 2014 Jan 30;33(5):539-49. (PMID: 23334327)
EMBO Rep. 2002 May;3(5):457-62. (PMID: 11964384)
Mol Cell. 2015 Apr 16;58(2):284-96. (PMID: 25866249)
Biomed Res Int. 2021 Jul 22;2021:6613439. (PMID: 34337035)
Biochem Biophys Res Commun. 2015 Aug 14;464(1):161-7. (PMID: 26116538)
EMBO Rep. 2002 Dec;3(12):1209-14. (PMID: 12446569)
BMC Complement Med Ther. 2022 Jan 25;22(1):21. (PMID: 35078445)
Int J Mol Sci. 2015 Dec 29;17(1):. (PMID: 26729093)
Int J Biol Sci. 2023 Jan 16;19(3):950-966. (PMID: 36778123)
Hepatology. 1998 Sep;28(3):751-5. (PMID: 9731568)
Genes Dev. 2002 Sep 1;16(17):2274-85. (PMID: 12208850)
معلومات مُعتمدة: EU Grant C3B; Università degli Studi di Trieste, Dipartimento di Scenze della Vita; Department of Science and Technology (DOST)-PCHRD; Programma di cooperazione Interreg V-A Italia -Slovenia 2014-2020; Italian Liver Foundation
المشرفين على المادة: EC 2.7.11.1 (Aurora Kinase A)
EC 2.7.11.1 (AURKA protein, human)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20240409 Date Completed: 20240802 Latest Revision: 20240804
رمز التحديث: 20240804
مُعرف محوري في PubMed: PMC11294426
DOI: 10.1111/cpr.13641
PMID: 38590119
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2184
DOI:10.1111/cpr.13641